2882-21-5

Usage

Uses

Used in Flavor and Fragrance Industry:
2-Methoxy-6-methylpyrazine is used as a flavoring agent for imparting nut-like aroma to foods and beverages. Its ability to mimic the scent of hazelnuts, almonds, and peanuts makes it a valuable ingredient in the creation of various food products, enhancing their taste and appeal to consumers.
Used in Coffee Industry:
As a coffee aroma enhancing agent, 2-methoxy-6-methylpyrazine is utilized to improve the overall aroma and flavor profile of coffee beverages. Its addition can elevate the sensory experience of coffee, making it more enjoyable for consumers.
Used in Pharmaceutical Industry:
2-Methoxy-6-methylpyrazine can be used for drug storage packaging, specifically for storing antiviral and antibacterial medications. Its presence in the packaging material can help maintain the stability and effectiveness of these medications, ensuring their potency and safety for use.
Aroma Threshold Values:
The detection threshold for 2-methoxy-6-methylpyrazine is relatively low, ranging from 3 to 7 parts per billion (ppb). This indicates that even trace amounts of the compound can be perceived by the human olfactory system, highlighting its potency as a flavoring agent and its importance in the flavor and fragrance industry.

Preparation

From 2-methylpyrazine by various routes.

InChI:InChI=1/C6H8N2O/c1-5-3-7-4-6(8-5)9-2/h3-4H,1-2H3

Upstream product

• 38557-71-0 2-chloro-6-methylpyrazine 
• 124-41-4 sodium methylate 
• 67-56-1 methanol 

Relevant academic research and scientific papers

COMBINATION TREATMENTS COMPRISING IMIDAZOPYRAZINONES FOR THE TREATMENT OF PSYCHIATRIC AND/OR COGNITIVE DISORDERS

The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of psychiatric and/or cognitive disorders such as for example Attention Deficit Hyperactivity Disorder (ADHD), depression, anxiety, narcolepsy, schizophrenia, cognitive impairment or cognitive impairment associated with schizophrenia (CIAS). Separate aspects of the invention are directed to the combined use of said compounds for the treatment of psychiatric and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of psychiatric and/or cognitive disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES

The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of neurodegenerative disorders such as for example Alzheimer's Disease, Parkinson's Disease or Huntington's Disease. Separate aspects of the invention are directed to the combined use of said compounds for the treatment of neurodegenerative and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of neurodegenerative disorders.

IMIDAZOPYRAZINONES AS PDE1 INHIBITORS

The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

Novel pyrazines from the myxobacterium Chondromyces crocatus and marine bacteria

The volatiles released by two strains of the myxobacterium Chondromyces crocatus and seven strains of marine Alpha-proteobacteria from the North Sea were collected using the CLSA or SPME headspace methods and analysed by GC-MS. In the extracts of C. crocatus 27 pyrazines were identified, belonging to different classes. 2,5-Dialkylpyrazines and related 3-methoxy-2,5- dialkylpyrazines dominated. Several pyrazines like 2-(1-methylethenyl)-5-(1- methylethyl)-pyrazine (7) and 3-methoxy-2,5-dialkylpyrazines with methyl, isopropyl, isobutyl or sec-butyl side-chains were obtained from natural sources for the first time. It was essential for the identification to rely on synthetic reference materials, which were obtained using Fuerstner's iron-catalysed coupling of chloropyrazines with Grignard reagents or condensation of azido ketones as key steps. The synthetic material allowed the identification of two previously unknown attractants of bacterial origin for the pineapple beetle Carpophilus humeralis, namely 3-methoxy-2-(1-methylpropyl)-5-(2-methylpropyl) pyrazine (17) and 3-methoxy-2,5-bis(1-methylpropyl)pyrazine (52). Several 2,5-dialkylpyrazines were identified in the extracts of the marine Alphaproteobacteria. The unique 2,5-dimethyl-3-(methylsulfanyl)pyrazine (67) represents a new type of natural pyrazine. Our results, together with literature reports, show that pyrazines are an important class of bacterial volatiles which might be more widespread than previously thought. Wiley-VCH Verlag GmbH & Co. KGaA, 2005.